Chongqing Zhifei Biological Products (300122) Stock Overview
Chongqing Zhifei Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
300122 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Chongqing Zhifei Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.48 |
| 52 Week High | CN¥26.00 |
| 52 Week Low | CN¥14.45 |
| Beta | 0.68 |
| 1 Month Change | -4.33% |
| 3 Month Change | -23.33% |
| 1 Year Change | -33.16% |
| 3 Year Change | -71.99% |
| 5 Year Change | -87.58% |
| Change since IPO | 140.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300122 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.0% | 0.2% | 4.9% |
| 1Y | -33.2% | 2.2% | 32.2% |
Return vs Industry: 300122 underperformed the CN Biotechs industry which returned 2.2% over the past year.
Return vs Market: 300122 underperformed the CN Market which returned 32.2% over the past year.
Price Volatility
| 300122 volatility | |
|---|---|
| 300122 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 300122 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300122's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,220 | Lingfeng Jiang | www.zhifeishengwu.com |
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine under the Mening A Con brand; and other developed products.
Chongqing Zhifei Biological Products Co., Ltd. Fundamentals Summary
| 300122 fundamental statistics | |
|---|---|
| Market cap | CN¥37.65b |
| Earnings (TTM) | -CN¥1.31b |
| Revenue (TTM) | CN¥10.91b |
Is 300122 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300122 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.91b |
| Cost of Revenue | CN¥8.20b |
| Gross Profit | CN¥2.71b |
| Other Expenses | CN¥4.02b |
| Earnings | -CN¥1.31b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 24.81% |
| Net Profit Margin | -12.00% |
| Debt/Equity Ratio | 47.6% |
How did 300122 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 14:52 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chongqing Zhifei Biological Products Co., Ltd. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Yizheng Yang | China International Capital Corporation Limited |
| Wentao Li | Citic Securities Co., Ltd. |